Canopy Growth (CGC) Other Operating Expenses (2019 - 2025)
Canopy Growth (CGC) reported Other Operating Expenses of -$4.0 million for Q4 2025, down 339.51% on a YoY basis from $1.7 million in Q4 2024, and down 1026.3% sequentially from -$358957.7 in Q3 2025.
Canopy Growth (CGC) Other Operating Expenses (2019 - 2025) Analysis & Trends
Canopy Growth (CGC) has 7 years of Other Operating Expenses data on file, last reported at -$4.0 million in Q4 2025.
- For the quarter ending Q4 2025, Other Operating Expenses fell 339.51% year-over-year to -$4.0 million; the trailing twelve-month figure through Mar 2026 stood at -$6.3 million (up 61.02% YoY), and the FY2026 full-year result was -$48.9 million, down 124.72% from the prior year.
- Other Operating Expenses retreated to -$4.0 million in Q4 2025, from -$358957.7 in the prior quarter.
- In the past five years, Other Operating Expenses ranged from a high of $22.3 million in Q3 2023 to a low of -$1.3 billion in Q3 2022.
- A 5-year average of -$87.0 million and a median of -$919866.1 in 2024 frame the typical range for Other Operating Expenses.
- Across the five-year window, Other Operating Expenses jumped 101.68% in 2023 and plunged 12993.95% in 2025, its largest moves.
- Tracing CGC's Other Operating Expenses over 5 years: stood at $5.4 million in 2021, then plunged by 405.0% to -$16.4 million in 2022, then plunged by 36.23% to -$22.3 million in 2023, then jumped by 95.88% to -$919866.1 in 2024, then tumbled by 339.51% to -$4.0 million in 2025.
- Business Quant data shows CGC's Other Operating Expenses at -$4.0 million in Q4 2025, -$358957.7 in Q3 2025, and -$1.9 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Canopy Growth | 197.77 Mn | -68.15 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -4.04 Mn |
| Sep 30, 2025 | -358,957.69 |
| Jun 30, 2025 | -1.91 Mn |
| Dec 31, 2024 | -919,866.15 |
| Sep 30, 2024 | -15.27 Mn |
| Jun 30, 2024 | -14,622.81 |
| Mar 31, 2024 | -47.15 Mn |
| Dec 31, 2023 | -22.34 Mn |
| Sep 30, 2023 | 22.30 Mn |
| Jun 30, 2023 | -1.44 Mn |
| Mar 31, 2023 | -299.53 Mn |
| Dec 31, 2022 | -16.40 Mn |
| Sep 30, 2022 | -1.32 Bn |
| Jun 30, 2022 | 6.32 Mn |
| Mar 31, 2022 | 8.55 Mn |
| Dec 31, 2021 | 5.38 Mn |
| Sep 30, 2021 | 12.67 Mn |
| Jun 30, 2021 | 10.68 Mn |
| Mar 31, 2021 | 15.42 Mn |
| Dec 31, 2020 | 25.85 Mn |